PIRS Palvella Therapeutics Inc.


$ 78.90 $ 0.79 (1.01 %)    

Thursday, 06-Nov-2025 15:30:42 EST
QQQ $ 613.75 $ -8.04 (-1.29 %)
DIA $ 470.28 $ -1.72 (-0.36 %)
SPY $ 672.12 $ -4.33 (-0.64 %)
TLT $ 89.69 $ 0.14 (0.15 %)
GLD $ 366.47 $ -0.73 (-0.2 %)
$ 75.75
$ 78.36
$ 78.47 x 6
$ 79.01 x 28
$ 76.00 - $ 81.52
$ 11.17 - $ 83.00
219,391
na
na
$ -0.33
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-of-qtorin-39-rapamycin-anhydrous-gel-for-the-treatment-of-microcystic-lymphatic-malformations

Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treat...

 palvella-therapeutics-and-pieris-pharmaceuticals-to-merge-creating-a-nasdaq-listed-entity-with-805m-cash-to-drive-development-of-novel-skin-disease-therapies

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing...

 pieris-pharmaceuticals-announces-1-for-80-reverse-stock-split

https://www.sec.gov/Archives/edgar/data/1583648/000143774924012442/ex_655549.htm

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION